In a pilot clinical trial of low risk PCa patients who were on active surveillance and had a repeat biopsy at 1 year (27% AAs), supplementation did not lower their PSA levels, but men on supplements had a decreased number of positive cores and no increase in Gleason Score (136). The gene discussed is KLK3; the disease is posterior cortical atrophy.